Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of national production capacity for PSMA radiotracers in the context of projected clinical demand for prostate cancer diagnosis.

Prostate-specific membrane antigen (PSMA) radiotracers are commissioned for use as part of PET-CT prostate cancer imaging, as set out in the published clinical commissioning policy. Access to PET-CT, as with any healthcare service, is closely monitored.